Trial site
Medical Center New Rehabilitation Center EOOD
Stara Zagora, 6001, BulgariaEU-13 widening countryNot linked to an institution yet
- 16running trials
- 17closed trials
The trials here
What the 33 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 211 trials
- Phase 2/31 trial
- Status
- Completed17 trials
- Recruiting10 trials
- Active, not recruiting6 trials
- Lead sponsor
- AstraZeneca6 trials
- Chiesi Farmaceutici S.p.A.5 trials
- Novo Nordisk A/S3 trials
- AstraZeneca AB2 trials
- Boehringer Ingelheim2 trials
- and 11 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma
2024-515162-13-00· Phase 3· AstraZeneca AB· Source
Completed
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source
Completed
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045· Phase 2· Amgen Inc.· Source
Completed
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879· Phase 2· Upstream Bio Inc.· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Sanofi· Source
Completed
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2)
2023-507665-25-00· Phase 3· Areteia Therapeutics Inc.· Source
Completed
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259· Phase 2· AstraZeneca· Source
Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
2023-507093-40-00· Phase 2· Genentech Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05037929· Phase 2· Genentech, Inc.· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04701983· Phase 3· Sanofi· Source
Completed
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878· Phase 3· AstraZeneca· Source
Completed
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634· Phase 3· AstraZeneca· Source
Report an error